Clinical Trials Logo

Interstitial Lung Disease clinical trials

View clinical trials related to Interstitial Lung Disease.

Filter by:

NCT ID: NCT02934750 Completed - Clinical trials for Interstitial Lung Disease

Pursed Lip Breathing in Interstitial Lung Disease

Start date: October 2016
Phase: N/A
Study type: Interventional

This randomized, cross-over study aims at describing the effect of pursed lip breathing on exercise-induced dyspnea and exercise capacity in patients with interstitial lung disease.

NCT ID: NCT02896205 Completed - Systemic Sclerosis Clinical Trials

Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease

MYILD
Start date: October 2016
Phase: Phase 3
Study type: Interventional

Systemic sclerosis is a multisystem disease and can involve the lungs in the form of ILD. Lung involvement is the most common cause of death in these patients. The present study is performed to study the efficacy of oral mycophenolate mofetil in treating early and mild ILD in patients of SSc. The efficacy and side effects of mycophenolate mofetil will be compared with that of oral placebo.

NCT ID: NCT02858791 Completed - Clinical trials for Pulmonary Hypertension

MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension

Start date: February 2013
Phase: N/A
Study type: Observational

The investigators will investigate the interrelationship of macrophage migration inhibitory factor (MIF) and free T4 in patients with PAH.

NCT ID: NCT02636452 Completed - Clinical trials for Interstitial Lung Disease

Cardiopulmonary Exercise Testing in Interstitial Lung Disease

Start date: October 31, 2013
Phase:
Study type: Observational

In patients with Interstitial lung diseases (ILD) dyspnea is the most often symptom. Pulmonary lung function tests often do not Show the dyspnea. Aim of the study is to evaluate cardiopulmonary exercise testing concerning therapeutic Monitoring in ILD.

NCT ID: NCT02630316 Completed - Clinical trials for Pulmonary Hypertension

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

Start date: February 3, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This was a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study included 326 patients at approximately 120 clinical trial centers. The treatment phase of the study lasted approximately 16 weeks. Patients who completed all required assessments were eligible to enter an open-label, extension study (RIN-PH-202).

NCT ID: NCT02622412 Completed - Cancer Clinical Trials

Evaluation of a Multi-professional Breathlessness Service for Patients With Breathlessness Due to Any Advanced Disease

BreathEase
Start date: March 2, 2015
Phase: N/A
Study type: Interventional

Breathlessness is a common and distressing symptom in patients with advanced diseases like cancer, chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF) or lung fibrosis, which broadly impacts on patients' quality of life and may result in high burden for carers. This single-blinded randomized controlled fast track trial evaluates the effectiveness of a multi-professional breathlessness service in patients with advanced and chronic diseases. The intervention group will get immediate access to the breathlessness service whereas the control group will receive standard care and get access to the service after a waiting time of eight weeks. Primary endpoints are mastery of breathlessness and quality of life, measured with the CRQ (Chronic Respiratory Questionnaire) as well as the reduction of symptom burden of patients and burden of carers. The evaluation of the cost effectiveness of the breathlessness service from the perspective of the German health system is a further study aim.

NCT ID: NCT02622022 Completed - Dyspnea Clinical Trials

Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease

MORPHILD
Start date: January 2016
Phase: Phase 4
Study type: Interventional

36 patients with interstitial lung disease will be randomized to 1 weeks treatment with morphine hydrochloride as oral linctus 5 mg, four times a day, and 5 mg as needed up to 4 times a day, or corresponding doses of placebo. VAS score for dyspnea will be evaluated after 1 hour and 1 week at follow up. Other questionnaires will also be evaluated (GAD-7, K-BUILD, Leicester score)

NCT ID: NCT02594839 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease

Start date: February 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The study evaluates the safety and the efficacy of the addition of intravenous transplantation of donor bone marrow mesenchymal stem cells in patients with idiopathic interstitial pneumonia or connective tissue disease associated with interstitial lung disease, which have actively progressing disease with rapid loss of pulmonary function on the background of routine treatment.

NCT ID: NCT02497144 Completed - Clinical trials for Interstitial Lung Disease

Neuromuscular Electrical Stimulation in Patients With Interstitial Lung Disease

Start date: July 15, 2015
Phase: N/A
Study type: Interventional

Decreased exercise capacity and quality of life, increased dyspnea and fatigue perception and hypoxemia during exercise is seen in patients with interstitial lung disease. Impaired ventilatory response, increased lung compliance, ventilation-perfusion mismatching and inadequate peripheral circulation causes decreased exercise capacity. Another important factor that induce decreased exercise capacity is peripheral muscle weakness. In literature, there is no study investigated effects of neuromuscular electrical stimulation on functional exercise capacity, respiratory and peripheral muscle strength, pulmonary functions, physical activity level, dyspnea and fatigue perception in patients with interstitial lung disease.

NCT ID: NCT02426229 Completed - Clinical trials for Interstitial Lung Disease

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

Start date: February 2016
Phase: Phase 1
Study type: Interventional

This study evaluates if dabigatran etexilate is safe for use in patients with Scleroderma and Interstitial Lung Disease. All patients will receive 75mg of dabigatran etexilate twice a day for 6 months.